Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

Researchers in the U.K. have published a major review of published data on physical side effects related to antidepressants such as changes in weight, blood pressure and heart rate.